174 related articles for article (PubMed ID: 32968828)
1. Venetoclax monotherapy for cutaneous blastic plasmacytoid dendritic cell neoplasm.
Schwede M; Tan IT; Atibalentja DF; Dickman MM; Rieger KE; Mannis GN
Ann Hematol; 2020 Dec; 99(12):2973-2975. PubMed ID: 32968828
[No Abstract] [Full Text] [Related]
2. Quick complete response achievement with venetoclax and azacitidine in a case of relapsed disseminated blastic plasmacytoid dendritic cell neoplasm.
Piccini M; Loscocco GG; Gianfaldoni G; Grieco P; Palmieri G; Pilerci S; Scappini B; Bosi A
Ann Hematol; 2020 Apr; 99(4):907-909. PubMed ID: 32030448
[No Abstract] [Full Text] [Related]
3. Low-dose venetoclax combined with azacitidine for blastic plasmacytoid dendritic cell neoplasm: a case report and literature review.
Wang Q; Zhao Y; Zang X; Zhou G; Liu Y; Feng Q; Li X; Wang W; Dong X; Liu X; Peng J; Liu C
Ann Hematol; 2024 Mar; 103(3):999-1005. PubMed ID: 38285081
[TBL] [Abstract][Full Text] [Related]
4. Tagraxofusp followed by combined azacitidine and venetoclax in blastic plasmacytoid dendritic cell neoplasm: A case report and literature review.
Samhouri Y; Ursu S; Dutton N; Tanvi V; Fazal S
J Oncol Pharm Pract; 2021 Jun; 27(4):990-995. PubMed ID: 32847479
[TBL] [Abstract][Full Text] [Related]
5. Achievement of rapid complete remission in an 87-year-old female patient with azacytidine-venetoclax for blastic plasmacytoid dendritic cell neoplasm.
Le Calloch R; Arnaud B; Le Clech L; Hutin P; Salmon F; Garnache Ottou F; Ianotto JC; Laribi K
Ann Hematol; 2022 Jun; 101(6):1347-1349. PubMed ID: 35249131
[No Abstract] [Full Text] [Related]
6. Venetoclax in a Patient with a Blastic Plasmacytoid Dendritic-Cell Neoplasm.
Agha ME; Monaghan SA; Swerdlow SH
N Engl J Med; 2018 Oct; 379(15):1479-1481. PubMed ID: 30304659
[No Abstract] [Full Text] [Related]
7. [Blastic plasmacytoid dendritic cell tumor treated with DVT regimen: a case report and literature review].
Shi J; Xu N; Niu Y; Jia SX; Yang CM; Fang MY
Zhonghua Xue Ye Xue Za Zhi; 2024 Jan; 45(1):86-89. PubMed ID: 38527844
[TBL] [Abstract][Full Text] [Related]
8. Venetoclax to treat relapsed blastic plasmacytoid dendritic cell neoplasm: A case-report and review of literature.
Beziat G; Ysebaert L; Gaudin C; Steinmeyer Z; Balardy L
Leuk Res; 2019 Oct; 85():106199. PubMed ID: 31415942
[No Abstract] [Full Text] [Related]
9. Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax.
Montero J; Stephansky J; Cai T; Griffin GK; Cabal-Hierro L; Togami K; Hogdal LJ; Galinsky I; Morgan EA; Aster JC; Davids MS; LeBoeuf NR; Stone RM; Konopleva M; Pemmaraju N; Letai A; Lane AA
Cancer Discov; 2017 Feb; 7(2):156-164. PubMed ID: 27986708
[TBL] [Abstract][Full Text] [Related]
10. Chronic myelomonocytic leukemia and blastic plasmacytoid dendritic cell neoplasm. A case report and systematic review.
Espasa A; Sorigue M; Tapia G; Cabezon M; Vergara S; Raya M; Navarro JT; Junca J; Zamora L; Xicoy B
Cytometry B Clin Cytom; 2021 May; 100(3):292-295. PubMed ID: 32830878
[No Abstract] [Full Text] [Related]
11. Blastic plasmacytoid dendritic cell neoplasm with transient response to pralatrexate.
Arranto C; Tzankov A; Halter J
Ann Hematol; 2017 Apr; 96(4):681-682. PubMed ID: 28013360
[No Abstract] [Full Text] [Related]
12. Blastic plasmacytoid dendritic cell neoplasm (BPDCN): a rare entity.
Lim MS; Lemmert K; Enjeti A
BMJ Case Rep; 2016 Jan; 2016():. PubMed ID: 26791132
[TBL] [Abstract][Full Text] [Related]
13. Blastic plasmacytoid dendritic cell neoplasm: a pathological illustration of two clinical cases.
Griffin JC; Aqel N; Siow W; Camilleri M; Ayto R
Ann Hematol; 2017 Oct; 96(10):1769-1770. PubMed ID: 28762083
[No Abstract] [Full Text] [Related]
14. A Case of Cutaneous Blastic Plasmacytoid Dendritic Cell Neoplasm Treated With a Bcl-2 Inhibitor.
Egger A; Coello D; Kirsner RS; Brehm JE
J Drugs Dermatol; 2021 May; 20(5):550-551. PubMed ID: 33938687
[TBL] [Abstract][Full Text] [Related]
15. Venetoclax plus hypomethylating agent in blast-phase myeloproliferative neoplasm: preliminary experience with 12 patients.
Gangat N; Morsia E; Foran JM; Palmer JM; Elliott MA; Tefferi A
Br J Haematol; 2020 Dec; 191(5):e120-e124. PubMed ID: 32945528
[No Abstract] [Full Text] [Related]
16. Venetoclax in relapsed/refractory blastic plasmacytoid dendritic cell neoplasm with central nervous system involvement: a case report and review of the literature.
Albiol N; Novelli S; Mozos A; Pratcorona M; Martino R; Sierra J
J Med Case Rep; 2021 Jun; 15(1):326. PubMed ID: 34172079
[TBL] [Abstract][Full Text] [Related]
17. Spontaneous regression of cutaneous blastic plasmacytoid dendritic cell neoplasm followed by acute monocytic leukemia evolving from myelodysplastic syndrome.
Yasuda H; Takaku T; Tomomatsu J; Hosone M; Tanaka H; Komatsu N
Intern Med; 2014; 53(23):2717-20. PubMed ID: 25447656
[TBL] [Abstract][Full Text] [Related]
18. In vivo and in vitro sensitivity of blastic plasmacytoid dendritic cell neoplasm to SL-401, an interleukin-3 receptor targeted biologic agent.
Angelot-Delettre F; Roggy A; Frankel AE; Lamarthee B; Seilles E; Biichle S; Royer B; Deconinck E; Rowinsky EK; Brooks C; Bardet V; Benet B; Bennani H; Benseddik Z; Debliquis A; Lusina D; Roussel M; Solly F; Ticchioni M; Saas P; Garnache-Ottou F
Haematologica; 2015 Feb; 100(2):223-30. PubMed ID: 25381130
[TBL] [Abstract][Full Text] [Related]
19. Venetoclax and hypomethylating agents in older/unfit patients with blastic plasmacytoid dendritic cell neoplasm.
Gangat N; Konopleva M; Patnaik MM; Jabbour E; DiNardo C; Al-Kali A; Foran JM; Granroth GL; Olteanu H; Kadia T; Tefferi A; Pemmaraju N
Am J Hematol; 2022 Feb; 97(2):E62-E67. PubMed ID: 34807470
[No Abstract] [Full Text] [Related]
20. More on Blastic Plasmacytoid Dendritic-Cell Neoplasms.
Pemmaraju N; Konopleva M; Lane AA
N Engl J Med; 2019 Feb; 380(7):695-6. PubMed ID: 30785714
[No Abstract] [Full Text] [Related]
[Next] [New Search]
